BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study Open Access
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123631
Published online Nov 15, 2026. doi: 10.4251/wjgo.123631
Combined low muscle mass and body mass index for prognosis in esophageal squamous cell carcinoma patients receiving immunochemoradiotherapy
Ling Xiao, Lin-Jie Li, Jia-Hua Lyu, Shi-Chuan Zhang, Long Liang, Department of Radiation, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, Sichuan Province, China
ORCID number: Jia-Hua Lyu (0000-0002-8560-1539); Long Liang (0009-0000-6578-8984).
Co-first authors: Ling Xiao and Lin-Jie Li.
Co-corresponding authors: Shi-Chuan Zhang and Long Liang.
Author contributions: Xiao L handled conceptualization, project administration, resources, and supervision; Xiao L and Li LJ managed data curation and visualization, they contributed equally to this article, they are the co-first authors of this manuscript; Xiao L and Lyu JH took charge of methodology; Lyu JH oversaw software; Xiao L, Li LJ, Lyu JH, Zhang SC, and Liang L contributed to investigation, validation, writing original draft, and writing review and editing; Liang L handled funding acquisition; Zhang SC and Liang L contributed equally to this article, they are the co-corresponding authors of this manuscript; and all authors thoroughly reviewed and endorsed the final manuscript.
AI contribution statement: Gemini 3 was used only for language polishing and improving academic English readability. It was not involved in study design, data analysis, result interpretation or conclusion generation. All scientific content was independently completed by the authors based on original clinical data.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Sichuan Cancer Hospital, approval No. SCCHEC-02-2020-019.
Informed consent statement: Informed consent was obtained from all subjects involved in the study.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Corresponding author: Long Liang, Associate Chief Physician, Department of Radiation, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, No. 55 Section 4, Renmin South Road, Chengdu 610041, Sichuan Province, China. lianglong@scszlyy.org.cn
Received: May 25, 2026
Revised: July 20, 2026
Accepted: September 4, 2026
Published online: November 15, 2026
Processing time: 165 Days and 14.1 Hours

Abstract
BACKGROUND

Locally advanced esophageal squamous cell carcinoma is widely treated with curative immunochemoradiotherapy. While low muscle mass (LMM) and body mass index (BMI) correlate with cancer prognosis, their joint prognostic role in this patient group is poorly defined.

AIM

To investigate the prognostic value of combined LMM and BMI stratification in this patient population, and evaluate the impact of body composition on survival.

METHODS

This single-center retrospective cohort study included 105 patients. Skeletal muscle index was calculated from computed tomography images at the L3 vertebral level, and LMM was defined using Asian-specific skeletal muscle index cutoff values. Restricted cubic spline analysis identified the optimal BMI cutoff. Survival was analyzed using the Kaplan-Meier method, and independent prognostic factors were identified using multivariable Cox regression.

RESULTS

Patients with LMM had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without LMM (all P < 0.001). BMI-stratified analysis showed significant heterogeneity in the prognostic value of LMM. LMM did not distinguish survival in patients with BMI < 22.0 kg/m2 but significantly predicted poorer PFS and OS in those with BMI ≥ 22.0 kg/m2 (both P < 0.001). Although patients with both LMM and low BMI had the poorest survival, multivariable analysis identified normal muscle mass combined with high BMI as an independent protective factor for PFS (hazard ratio = 0.316, 95% confidence interval: 0.147-0.678; P = 0.003) and OS (hazard ratio = 0.265, 95% confidence interval: 0.119-0.588; P = 0.001).

CONCLUSION

Among patients with esophageal squamous cell carcinoma receiving immunochemoradiotherapy, LMM has greater prognostic value in those with a high BMI. Combined assessment of LMM and BMI improves risk stratification and may facilitate individualized treatment planning.

Key Words: Esophageal squamous cell carcinoma; Immunochemoradiotherapy; Skeletal muscle index; Low muscle mass; Body mass index

Core Tip: In this retrospective study of 105 patients with esophageal squamous cell carcinoma receiving immunochemoradiotherapy, we found that the prognostic value of low muscle mass is highly dependent on body mass index (BMI). Low muscle mass served as a strong independent adverse prognostic factor only in patients with BMI ≥ 22.0 kg/m2, but showed no predictive efficacy in individuals with lower BMI, demonstrating marked BMI-dependent heterogeneity. This finding provides a novel basis for personalized risk stratification and clinical management of esophageal squamous cell carcinoma patients.



INTRODUCTION

Esophageal cancer is a major global public health problem that poses a serious threat to human health and is among the malignancies with the poorest prognosis[1]. The latest national cancer surveillance data indicate that the burden of esophageal cancer remains substantial in China. In 2022, China recorded 224000 new cases and 187500 deaths from esophageal cancer, ranking sixth in incidence and fourth in mortality among all malignancies[2,3]. Esophageal squamous cell carcinoma (ESCC) is the predominant histological subtype, accounting for approximately 85% of all esophageal cancer cases. Most patients are diagnosed at a locally advanced or advanced stage and therefore miss the opportunity for curative surgical resection[4,5]. For patients with unresectable locally advanced ESCC, definitive concurrent chemoradiotherapy (CRT) remains the standard treatment. Previous clinical studies have demonstrated that CRT preserves organ function while providing superior efficacy compared with radiotherapy alone[6-8]. Nevertheless, this treatment still has important limitations, including unsatisfactory long-term survival, with a 3-year survival rate of only 40%-50%, as well as risks of late toxicities and tumor recurrence[9,10].

With advances in cancer therapy, immunotherapy, particularly programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors, has rapidly evolved and has been widely incorporated into multiple treatment strategies for esophageal cancer[11-13]. Currently, immunotherapy combined with chemoradiotherapy has emerged as an important therapeutic approach for locally advanced and advanced ESCC, significantly improving survival outcomes in selected patients[14,15]. For example, the phase II multicenter randomized controlled EC-CRT-002 trial demonstrated that an immune-first strategy (induction immunotherapy plus chemotherapy followed by CRT) achieved promising antitumor efficacy in patients with unresectable locally advanced ESCC. Patients receiving short-course immunotherapy achieved a clinical complete response rate of 70.2% at 3 months after radiotherapy, with 1-year progression-free survival (PFS) and overall survival (OS) rates of 71.9% and 84.2%, respectively. This optimized regimen demonstrated superior efficacy and manageable safety compared with conventional CRT[16]. However, substantial prognostic heterogeneity remains among patients receiving this regimen, and some derive limited clinical benefit. Therefore, simple, widely applicable biomarkers are urgently needed to improve prognostic stratification and guide individualized treatment decisions.

Sarcopenia is a syndrome characterized by the progressive and generalized loss of skeletal muscle mass, strength, and physical function and has a high prevalence among patients with malignancies[17-19]. Its pathogenesis is closely associated with tumor-induced catabolism, treatment-related injury, and systemic inflammation. Accumulating evidence indicates that sarcopenia objectively reflects nutritional status and physical function and serves as a reliable biomarker for predicting treatment tolerance, treatment-related toxicity, and long-term survival[20-23]. A recent systematic review and meta-analysis by Fang et al[24] further confirmed that sarcopenia is significantly associated with poorer OS and a higher risk of postoperative complications in patients with esophageal cancer, providing robust evidence for its prognostic value across different treatment modalities. Body mass index (BMI) is a simple and widely used indicator of nutritional status that also has prognostic value in patients with cancer[25-27]. However, BMI cannot distinguish skeletal muscle from adipose tissue and therefore fails to identify occult muscle depletion in patients with normal or even elevated BMI[28,29]. This important limitation was first systematically demonstrated in landmark studies by the Alberta research group. Prado et al[30] introduced the concept of sarcopenic obesity in patients with gastrointestinal and respiratory tract malignancies and showed that obese patients with concurrent low muscle mass (LMM) had significantly poorer functional status and survival outcomes. Martin et al[31] subsequently demonstrated that computed tomography (CT)-defined skeletal muscle depletion is a powerful independent prognostic factor regardless of BMI category, highlighting that body composition assessment provides prognostic information beyond BMI alone. These findings underscore the limitations of relying solely on BMI for accurate prognostic stratification.

To date, the relationship between LMM and BMI has not been fully elucidated in patients with ESCC, particularly those receiving immunochemoradiotherapy. Whether these two indicators provide complementary prognostic information and can be integrated into a more comprehensive body composition assessment model to improve risk stratification and clinical management remains unclear.

Therefore, in this retrospective cohort study, we enrolled patients with locally advanced ESCC treated with immunotherapy combined with chemoradiotherapy. The objectives were to: (1) Characterize the clinical features of LMM and its association with survival outcomes; (2) Investigate the relationship between BMI and LMM and develop a BMI-based predictive model for LMM; and (3) Evaluate the prognostic value of the combined assessment of LMM and BMI and identify independent prognostic factors for survival. These findings may provide evidence to support individualized prognostic assessment and targeted clinical management in patients with ESCC.

MATERIALS AND METHODS
Study population

This retrospective clinical study enrolled 105 patients with locally advanced ESCC who received definitive chemoradiotherapy combined with immunotherapy at Sichuan Cancer Hospital between October 2019 and December 2023.

The inclusion criteria were as follows: (1) Histopathologically confirmed ESCC; (2) Unresectable locally advanced disease (stage III-IVa) according to the eighth edition of the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system; (3) Completion of definitive radiotherapy combined with chemotherapy and programmed death-1/PD-L1 inhibitor immunotherapy with curative intent; (4) Availability of complete pretreatment abdominal CT images, anthropometric measurements, and clinical laboratory data; and (5) Absence of distant metastasis or another primary malignancy.

The exclusion criteria were as follows: (1) Distant organ metastasis; (2) Previous antitumor treatment, including chemoradiotherapy, targeted therapy, or immunotherapy; (3) Severe infection or organ failure; (4) CT images with severe artifacts or incomplete clinical or follow-up data; and (5) Failure to complete the planned course of definitive immunochemoradiotherapy.

Clinical data collection

Baseline clinical data, including age, sex, smoking and drinking history, tumor location, clinical stage, radiotherapy dose, and pretreatment nutritional and laboratory parameters (routine blood test results, serum albumin, prealbumin, blood glucose, and blood lipid levels), were extracted from the hospital’s electronic medical record system.

Body composition measurement and grouping criteria

Pretreatment abdominal CT images were retrieved from the hospital’s Picture Archiving and Communication System. Two senior radiologists, blinded to the study outcomes, used SliceOmatic version 5.0 software to delineate the skeletal muscles (including the psoas, erector spinae, and abdominal wall muscles) at the third lumbar vertebral (L3) level using a Hounsfield unit threshold of -29 to +150. The skeletal muscle cross-sectional area was then measured. The skeletal muscle index (SMI) was calculated as skeletal muscle cross-sectional area (cm2) divided by height squared (m2). According to Asian-specific cutoff values, LMM was defined as an SMI < 40.8 cm2/m2 for men and < 34.9 cm2/m2 for women; patients not meeting these criteria were classified as having normal muscle mass (NMM)[32,33]. BMI was calculated as body weight (kg) divided by height squared (m2). All anthropometric measurements were obtained within one week before initiation of definitive chemoradiotherapy. Patients were measured while wearing light clothing and no shoes using calibrated electronic scales and stadiometers. BMI was analyzed in two ways: (1) As a categorical variable, with patients classified as underweight (< 18.5 kg/m2), normal weight (18.5-23.9 kg/m2), or overweight/obese (≥ 24.0 kg/m2) according to the Guidelines for the Prevention and Control of Adult Overweight and Obesity in China (Revised 2020)[34]; and (2) As a continuous variable to evaluate the nonlinear association between BMI and LMM using restricted cubic spline (RCS) analysis[35]. Finally, patients were categorized into four groups according to BMI and muscle mass status: LMM with low BMI, LMM with high BMI, NMM with low BMI, and NMM with high BMI.

Clinical follow-up

Patients underwent standardized follow-up through outpatient visits and telephone interviews. Follow-up assessments were performed every 3 months during the first year after treatment and every 6 months thereafter. Evaluations included physical examination, laboratory testing, chest CT, and esophageal imaging. The primary endpoints were OS and PFS. OS was defined as the interval from ESCC diagnosis to death from any cause or the last follow-up. PFS was defined as the interval from treatment completion to disease progression, death, or the last follow-up.

Statistical analysis

Statistical analyses and data visualization were performed using RStudio version 4.3.1. A two-sided P < 0.05 was considered statistically significant. Categorical variables are presented as frequencies and percentages and were compared using the χ2 test or Fisher’s exact test, as appropriate. Continuous variables are presented as the mean ± SD or median (interquartile range), depending on their distribution, and were compared using the independent-samples t test. The Kaplan-Meier method was used to estimate OS and PFS, and differences between groups were assessed using the log-rank test. Multivariable logistic regression analysis was performed to identify independent factors associated with LMM. RCS analysis was used to evaluate the nonlinear association between BMI and the risk of LMM and to identify the optimal BMI cutoff. Univariate and multivariable Cox proportional hazards regression models were constructed to identify independent prognostic factors for OS and PFS. A BMI-based predictive model for LMM was subsequently developed. Its discrimination and calibration were evaluated using receiver operating characteristic curves and calibration curves, respectively.

RESULTS
Baseline characteristics and clinical outcome correlations

Altogether, 105 patients with locally advanced ESCC receiving immunochemoradiotherapy were enrolled, with 48 (45.7%) classified as LMM and 57 (54.3%) as NMM based on baseline SMI (Table 1). At baseline, the LMM group showed distinct clinical characteristics compared with the NMM group, with significant intergroup differences in sex, smoking history, BMI distribution, and nutritional parameters (all P < 0.05). Notably, patients with LMM were predominantly male (43.8% vs 39.0%, P = 0.001) and had a higher proportion of smokers (38.1% vs 29.5%, P = 0.002). Regarding BMI, patients with LMM were more likely to be underweight (BMI < 18.5 kg/m2, 6.7% vs 0%) and less likely to be overweight or obese (BMI ≥ 24.0 kg/m2, 5.7% vs 21.0%, P < 0.001). They also had significantly lower serum albumin (37.4 ± 3.0 g/L vs 38.9 ± 3.4 g/L, P = 0.014) and triglyceride levels (median: 1.04 mmol/L vs 1.19 mmol/L, P = 0.016). No significant intergroup differences were observed in age, drinking history, tumor location, TNM stage, routine blood parameters, prealbumin, total cholesterol, blood glucose, or radiotherapy dose (all P > 0.05). To further visualize the associations between these baseline characteristics, including LMM status, and clinical outcomes, patients were stratified according to treatment response (response vs progression) and survival status (alive vs deceased). The matrix of ring charts (Figure 1) comprehensively illustrates the proportional distribution of key characteristics across the different outcome subgroups, highlighting how LMM and other baseline factors varied according to treatment response and survival status.

Figure 1
Figure 1 Clinical characteristics by treatment response and survival status.
Table 1 Participant baseline characteristics stratified by low muscle mass, n (%)/mean ± SD.
Characteristics
Overall
NMM
LMM
P value
n1055748-
Sex0.001
Female18 (17.1)16 (15.2)2 (1.9)
Male87 (82.9)41 (39)46 (43.8)
Age, median (IQR)65 (58, 69)66 (61, 69)64 (58, 69)0.434
Smoking history0.002
No34 (32.4)26 (24.8)8 (7.6)
Yes71 (67.6)31 (29.5)40 (38.1)
Alcoholhistory0.075
No38 (36.2)25 (23.8)13 (12.4)
Yes67 (63.8)32 (30.5)35 (33.3)
Tumorlocation0.825
Cervical15 (14.3)9 (8.6)6 (5.7)
Upper thoracic26 (24.8)15 (14.3)11 (10.5)
Middle thoracic43 (41.0)21 (20.0)22 (21.0)
Lower thoracic21 (20.0)12 (11.4)9 (8.6)
T0.212
11 (1.0)0 (0.0)1 (1.0)
23 (2.9)3 (2.9)0 (0.0)
389 (84.8)49 (46.7)40 (38.1)
412 (11.4)5 (4.8)7 (6.7)
N0.051
01 (1.0)1 (1.0)0 (0.0)
117 (16.2)13 (12.4)4 (3.8)
263 (60.0)34 (32.4)29 (27.6)
324 (22.9)9 (8.6)15 (14.3)
TNM0.482
III82 (78.1)46 (43.8)36 (34.3)
IV23 (21.9)11 (10.5)12 (11.4)
WBC, median (IQR)6.05 (5.13, 7.27)6.02 (5.15, 7.42)6.05 (5.07, 7.24)0.714
HGB, median (IQR)130 (120, 141)133 (120, 141)127 (120, 138)0.214
PLT, median (IQR)199 (159, 237)194 (147, 233)205.5 (161, 250)0.320
NC, median (IQR)4.10 (3.05, 5.24)4.11 (3.15, 5.28)4.09 (2.95, 5.22)0.700
LC1.36 ± 0.481.35 ± 0.461.37 ± 0.510.841
MC, median (IQR)0.43 (0.32, 0.52)0.425 (0.31, 0.56)0.44 (0.32, 0.50)0.860
ALB38.20 ± 3.2838.92 ± 3.3537.35 ± 3.000.014
PA195.11 ± 46.84203.05 ± 51.46185.67 ± 39.130.058
Triglycerides, median (IQR)1.15 (0.93, 1.44)1.19 (1, 1.47)1.035 (0.86, 1.29)0.016
Total cholesterol, median (IQR)4.44 (3.76, 5.07)4.65 (4.04, 5.28)4.33 (3.72, 4.85)0.189
Blood glucose, median (IQR)4.82 (4.46, 5.13)4.92 (4.56, 5.25)4.675 (4.44, 4.97)0.060
RT dose, median (IQR)60 (60, 60)60 (56, 60)60 (60, 60)0.561
BMI< 0.001
< 18.5 kg/m27 (6.7)0 (0)7 (6.7)
18.5-24.0 kg/m270 (66.7)35 (33.3)35 (33.3)
≥ 24.0 kg/m228 (26.7)22 (21)6 (5.7)
Analysis of correlative factors and construction of an LMM prediction model in patients with esophageal cancer

Given the significant association between LMM and poor baseline prognosis, we further explored the factors associated with LMM in patients with esophageal cancer receiving definitive chemoradiotherapy combined with immunotherapy and subsequently constructed a BMI-based LMM prediction model (Figure 2). First, violin plots (Figure 2A-C) illustrate the distribution of BMI across different clinical subgroups. BMI was significantly lower in the LMM group than in the NMM group (Figure 2A, P < 0.001). In the survival subgroups, deceased patients had a slightly lower BMI than surviving patients, although the difference was only marginally significant (Figure 2B, P = 0.056). No significant difference in BMI distribution was observed between patients with stage III and stage IV disease (Figure 2C, P = 0.379). Multivariate logistic regression analysis was performed to identify independent risk factors for LMM (Figure 2D). Female sex was associated with a significantly lower risk of LMM [odds ratio (OR) = 0.035, 95% confidence interval (CI): 0.002-0.549, P = 0.0017]. Each 1-kg/m2 increase in BMI was associated with a 70.1% increase in the odds of LMM (OR = 1.701, 95%CI: 1.302-2.223, P < 0.001). In contrast, TNM stage and blood glucose, triglyceride, and total cholesterol levels were not significantly associated with LMM (all P > 0.05). Given the strong association between BMI and LMM, RCS analysis was performed to characterize their relationship (Figure 2E). The overall association between BMI and LMM was statistically significant (overall P = 0.0002). The test for nonlinearity was marginally significant (P = 0.08), suggesting that the association was predominantly linear rather than nonlinear. Accordingly, a BMI value of 22.0 kg/m2 was identified as the optimal exploratory cutoff for BMI stratification based on the trend of the RCS curve.

Figure 2
Figure 2 Low muscle mass and associated factors in esophageal cancer patients. A-C: Present violin plots of body mass index (BMI) distribution across different clinical subgroups; D: A forest plot of multivariable logistic regression analysis for factors associated with low muscle mass (LMM); E: Depicts the nonlinear association between BMI and LMM using restricted cubic spline analysis; F and G: Display the receiver operating characteristic curve and calibration curve of the LMM prediction model, respectively. OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; TNM: Tumor-node-metastasis; AUC: Area under the curve; FPR: False-positive rate; TPR: True-positive rate.

When BMI was < 22.0 kg/m2, the risk of LMM decreased as BMI increased (OR = 0.145, 95%CI: 0.061-0.342). Conversely, when BMI exceeded 22.0 kg/m2, the risk of LMM increased sharply with increasing BMI (OR = 6.899, 95%CI: 2.920-16.298). Based on these findings, a BMI-based LMM prediction model was established and validated for its discrimination and calibration performance. The receiver operating characteristic curve (Figure 2F) demonstrated an area under the curve of 0.805 (95%CI: 0.718-0.891). The calibration curve (Figure 2G) showed good agreement between the predicted probabilities and the observed outcomes.

Prognostic stratification of patients with esophageal cancer based on LMM and BMI status

Kaplan-Meier survival analysis combined with multiple comparisons was performed to compare OS and PFS across different subgroups (Figure 3). In the overall cohort, patients with LMM had significantly worse PFS (Figure 3A) and OS (Figure 3E) than those without LMM, with both differences reaching statistical significance according to the log-rank test (both P < 0.001). These findings confirmed that LMM was an adverse prognostic factor in the overall study population. Further stratification according to combined LMM and BMI status (Figure 3B and F) revealed a clear prognostic gradient across the four subgroups. Patients with LMM and low BMI had the poorest survival outcomes, whereas those with NMM and high BMI had the most favorable prognosis. Significant differences were observed among the four subgroups for both PFS (P = 0.003) and OS (P = 0.001).

Figure 3
Figure 3 Survival analysis stratified by LMM and body mass index status in esophageal cancer patients. A-D: Present progression-free survival (PFS); E-H: Present overall survival (OS). A and E: Comparison of PFS and OS between sarcopenic and non-sarcopenic patients in the entire cohort; B and F: Combined stratification by low muscle mass (LMM) and body mass index (BMI) status (four subgroups: LMM + low BMI, normal muscle mass + high BMI, LMM + high BMI, normal muscle mass + low BMI) for PFS and OS in the entire cohort; C and G: Stratified analyses of PFS and OS by LMM status in patients with BMI < 22 kg/m2; D and H: Stratified analyses of PFS and OS by LMM status in patients with BMI ≥ 22 kg/m2. NMM: Normal muscle mass; LMM: Low muscle mass; BMI: Body mass index.

The principal finding of this study was the marked prognostic heterogeneity of LMM according to BMI status (Figure 3C-H). Among patients with BMI < 22 kg/m2 (Figure 3C and G), the PFS and OS curves largely overlapped between the LMM and NMM groups, with no significant differences detected by the log-rank test (P = 0.110 for PFS and P = 0.128 for OS). These findings suggest that LMM provided limited prognostic discrimination in patients with low BMI. In contrast, among patients with BMI ≥ 22 kg/m2 (Figure 3D and H), those with LMM exhibited significantly poorer PFS and OS than those with NMM (both P < 0.001). These findings demonstrate that LMM had substantially greater prognostic value in patients with higher BMI, representing the principal novel finding of this study.

Independent prognostic factors affecting survival in patient with esophageal cancer

Cox proportional hazards regression models were used to identify independent prognostic factors for OS and PFS. Univariate analysis demonstrated that combined LMM and BMI status was an important prognostic indicator. Using the LMM plus low BMI group as the reference, the NMM plus high BMI group had significantly lower risks of mortality [hazard ratio (HR) = 0.259, 95%CI: 0.119-0.562, P < 0.001] and disease progression (HR = 0.316, 95%CI: 0.147-0.678, P = 0.003). The NMM plus low BMI group showed a marginal reduction in mortality risk (HR = 0.426, 95%CI: 0.172-1.053, P = 0.064). No significant difference in survival risk was observed between the LMM plus high BMI group and the reference group. Additionally, radiotherapy dose showed a marginal association with OS (HR = 0.953, 95%CI: 0.902-1.007, P = 0.087). Other baseline variables, including sex, age, smoking history, drinking history, tumor location, and laboratory parameters, were not significantly associated with prognosis in the univariate analysis. After adjustment for potential confounding factors in the multivariate Cox regression model, combined LMM and BMI status remained an independent prognostic factor. For OS, patients in the NMM plus high BMI group had only 26.5% of the mortality risk of those in the reference group (HR = 0.265, 95%CI: 0.119-0.588, P = 0.001). The NMM plus low BMI group also had a significantly lower mortality risk (HR = 0.327, 95%CI: 0.116-0.925, P = 0.035). Furthermore, radiotherapy dose was identified as an independent protective factor for OS, with each 1-Gy increase associated with a 6.5% reduction in mortality risk (HR = 0.935, 95%CI: 0.877-0.997, P = 0.039). For PFS, only the NMM plus high BMI group exhibited a significantly lower risk of disease progression than the reference group (HR = 0.316, 95%CI: 0.147-0.678, P = 0.003; Tables 2 and 3).

Table 2 Univariate and multivariate Cox regression analyses of factors associated with progression-free survival.
CharacteristicsTotal (n)Univariate analysis
Multivariate analysis
HR (95%CI)
P value
HR (95%CI)
P value
Sex105----
Female18Reference---
Male871.953 (0.765-4.988)0.162--
Age1051.017 (0.973-1.062)0.452--
Smoking history105----
No34Reference---
Yes711.015 (0.545-1.890)0.964--
Alcohol history105----
No38Reference---
Yes670.865 (0.473-1.583)0.639--
Tumor location105----
Cervical15Reference---
Upper thoracic262.716 (0.870-8.481)0.086--
Middle thoracic432.540 (0.865-7.456)0.090--
Lower thoracic212.207 (0.677-7.195)0.189--
TNM105----
III82Reference---
IV231.690 (0.885-3.226)0.112--
Triglycerides1051.091 (0.725-1.642)0.676--
Total cholesterol1051.163 (0.867-1.559)0.313--
Blood glucose1050.960 (0.748-1.232)0.748--
HGB1051.007 (0.987-1.026)0.504--
ALB1051.030 (0.940-1.128)0.524--
PA1050.999 (0.993-1.005)0.793--
RT dose1050.961 (0.907-1.018)0.178--
SMI-BMI105----
LMM and low BMI35Reference-Reference-
NMM and high BMI410.316 (0.147-0.678)0.00310.316 (0.147-0.678)0.0031
LMM and high BMI131.272 (0.557-2.902)0.5681.272 (0.557-2.902)0.568
NMM and low BMI160.431 (0.173-1.071)0.0700.431 (0.173-1.071)0.070
Table 3 Univariate and multivariate Cox regression analyses of factors associated with overall survival.
CharacteristicsTotal (n)Univariate analysis
Multivariate analysis
HR (95%CI)
P value
HR (95%CI)
P value
Sex105----
Female18Reference-Reference-
Male872.179 (0.852-5.572)0.1041.330 (0.474-3.733)0.589
Age1051.015 (0.972-1.060)0.497--
Smoking history105----
No34Reference---
Yes711.024 (0.550-1.907)0.939--
Alcohol history105----
No38Reference---
Yes670.921 (0.502-1.688)0.790--
Tumor location105----
Cervical15Reference---
Upper thoracic262.618 (0.838-8.179)0.098--
Middle thoracic432.427 (0.828-7.114)0.106--
Lower thoracic212.152 (0.661-7.004)0.203--
TNM105----
III82Reference---
IV231.473 (0.770-2.817)0.242--
Triglycerides1051.013 (0.670-1.531)0.951--
Total cholesterol1051.164 (0.862-1.572)0.321--
Blood glucose1050.979 (0.767-1.251)0.866--
HGB1051.006 (0.987-1.026)0.515--
ALB1051.008 (0.921-1.103)0.865--
PA1050.999 (0.993-1.005)0.649--
RT dose1050.953 (0.902-1.007)0.0870.935 (0.877-0.997)0.0391
SMI-BMI105--
LMM and low BMI35Reference-Reference
NMM and high BMI410.259 (0.119-0.562)< 0.00110.265 (0.119-0.588)0.0011
LMM and high BMI131.088 (0.477-2.482)0.8411.030 (0.450-2.358)0.944
NMM and low BMI160.426 (0.172-1.053)0.0640.327 (0.116-0.925)0.0351
DISCUSSION

Chemoradiotherapy combined with immunotherapy serves as a critical therapeutic strategy for patients with advanced ESCC; however, significant survival heterogeneity persists among this population. Currently, simple and reliable baseline somatic biomarkers for the prognostic evaluation of this patient population remain lacking[6,36]. The application of sarcopenia or BMI has inherent limitations and cannot comprehensively reflect human body composition. In the present study, baseline CT-defined LMM was identified as an independent adverse prognostic factor in patients with ESCC receiving chemoradiotherapy combined with immunotherapy. Further RCS analyses demonstrated that the correlation between BMI and LMM risk was predominantly linear, and 22.0 kg/m2 was selected as an exploratory stratification threshold based on the trend of the fitted curve. Sex and BMI were verified as independent influencing factors for LMM. The BMI-based predictive model exhibited favorable discrimination ability, and the combined stratification of LMM and BMI generated a steady prognostic gradient. More importantly, we further confirmed that the prognostic predictive effect of LMM was not universally applicable, but presented obvious BMI-dependent heterogeneity, which further improved the clinical application value of this combined indicator.

Accumulated evidence has confirmed the correlation between sarcopenia and poor prognosis in esophageal cancer. Sarcopenia is an independent adverse prognostic factor associated with inferior OS in patients with ESCC receiving definitive chemoradiotherapy (HR = 2.84)[21]. Moreover, sarcopenia occurring after neoadjuvant chemoradiotherapy or > 12% reduction in SMI during treatment is correlated with shorter survival and higher postoperative complication risk[20]. Persistent inflammatory and immune disorders trigger skeletal muscle depletion, and the two influence each other dynamically thereafter. Nevertheless, the above evidence only originates from patients treated with definitive chemoradiotherapy alone, and few studies have verified whether this prognostic rule still applies to regimens combined with immunotherapy.

With the widespread application of immunotherapy, multiple large-scale phase III clinical trials have validated that treatment with immune checkpoint inhibitors combined with chemotherapy or chemoradiotherapy significantly improve the survival outcomes of patients with locally advanced or metastatic ESCC, establishing this combination regimen as a new standard treatment. For instance, the CheckMate 648 trial conducted by Doki et al[37] demonstrated that nivolumab combined with chemotherapy significantly prolonged the median OS from 9.1 months to 15.4 months in PD-L1-positive advanced ESCC patients (HR = 0.54, P < 0.001). Similarly, the ORIENT-15 trial by Lu et al[38], the SKYSCRAPER-08 trial by Hsu et al[14], and the EC-CRT-002 trial by Chen et al[16] have separately confirmed the significant survival benefits of sintilimab, tiragolumab plus atezolizumab, and tislelizumab in their combination regimens. Essentially, immunochemoradiotherapy differs from conventional chemoradiotherapy in terms of therapeutic mechanisms, systemic inflammation, and immune microenvironment, possibly altering the pathophysiological process and prognostic value of sarcopenia. Notably, Kosumi et al[22] found that a large waist circumference was significantly correlated with superior disease control and PFS in unresectable or recurrent esophageal cancer patients receiving immunotherapy (HR = 0.73, P = 0.0002), suggesting that the prognostic significance of body composition may undergo unique changes in the immunotherapy era. Currently, studies focusing on the prognostic value of sarcopenia in the emerging immunochemoradiotherapy setting remain scarce. Although Zeng et al[39] have explored the predictive efficacy of relevant biomarkers, high-quality prospective evidence targeting this specific treatment regimen is still insufficient. The present study confirmed that in patients with advanced ESCC receiving immunochemoradiotherapy, LMM is associated with significantly shorter median OS (17.0 months vs 24.5 months) and PFS (15.0 months vs 24.0 months). Multivariate Cox regression analysis further identified LMM as an independent adverse prognostic factor for both OS and PFS, which was consistent with the conclusions of previous basic cohort studies.

As a widely used simple nutritional marker in clinical practice, BMI cannot distinguish skeletal muscle from adipose tissue and thus has inherent limitations for independent prognostic assessment, which has been verified in multiple malignancies. A meta-analysis on gastric cancer confirmed that sarcopenic obesity defined as high BMI with reduced muscle mass was closely linked to poor OS and severe postoperative complications[29]. Although several studies have combined BMI and sarcopenia for prognostic exploration, most analyses adopted linear correlation models, and relevant stratified researches focusing on ESCC patients receiving immunochemoradiotherapy remain insufficient[39]. Based on RCS regression, we selected 22.0 kg/m2 as an optimal exploratory BMI stratification threshold according to the curve’s variation trend within our cohort. This cut-off was adopted to subgroup patients for subsequent effect modification analysis, consistent with cut-off values reported in prior Asian population-based studies[27,40]. Notably, the association between BMI and sarcopenia incidence is distinct from their combined prognostic effect. Our study found that LMM exhibited no prognostic value for survival stratification in patients with a BMI below 22.0 kg/m2. We hypothesize that widespread tumor-related malnutrition in this patient population may mask the independent prognostic effect of isolated muscle wasting, resulting in a homogeneous survival outcome. In contrast, skeletal muscle depletion in patients with a BMI of 22.0 kg/m2 or higher is often clinically unrecognized. Differing from low-BMI patients, this covert muscle loss acts as a steady and reliable adverse prognostic factor, enabling effective survival discrimination among high-BMI individuals. Clinically, more attention should be paid to easily neglected sarcopenic obesity individuals, rather than merely focusing on the superficial poor survival trend of low-BMI sarcopenic patients. In the immunochemoradiotherapy era, elevated BMI may mask underlying muscle loss, making single BMI assessment unreliable for nutritional and prognostic evaluation, which is consistent with previous pancreatic cancer research conclusions[41]. Joint stratification based on sarcopenia and BMI can form stable prognostic gradients and serve as a more powerful independent prognostic indicator than single index evaluation.

Several limitations of this study should be acknowledged. Firstly, sarcopenia was solely assessed using radiological SMI without incorporating muscle density and physical function indicators, including grip strength, which may compromise evaluation comprehensiveness and subtype differentiation. Secondly, the present investigation was a single-center retrospective study with a limited sample size, and the follow-up duration was insufficient to evaluate the long-term prognostic value beyond 5 years. Furthermore, the present study only analyzed the correlation between the patients’ baseline characteristics and prognosis, without exploring the modifying effects of interventions, including nutritional supplementation and physical exercise, on muscle status and survival outcomes. Finally, the specific biological mechanisms underlying the combined prognostic effect of LMM and BMI require further validation through basic experiments and prospective clinical trials.

CONCLUSION

The present study demonstrated a significant association between pretreatment BMI and the risk of LMM in patients with ESCC receiving immunochemoradiotherapy. Notably, the prognostic value of LMM was highly dependent on BMI status. This stratified assessment model provides a novel approach to precise prognostic evaluation and may facilitate individualized clinical intervention and nutritional management for patients with advanced ESCC.

ACKNOWLEDGEMENTS

The authors thank the Institutional Review Board of Sichuan Cancer Hospital and Institute, the radiology and clinical database teams, our colleagues for their valuable support and discussions, and all patients whose data formed the basis of this study.

References
1.  Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 16785]  [Cited by in RCA: 18093]  [Article Influence: 9046.5]  [Reference Citation Analysis (55)]
2.  Qi L, Sun M, Liu W, Zhang X, Yu Y, Tian Z, Ni Z, Zheng R, Li Y. Global esophageal cancer epidemiology in 2022 and predictions for 2050: A comprehensive analysis and projections based on GLOBOCAN data. Chin Med J (Engl). 2024;137:3108-3116.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 54]  [Reference Citation Analysis (0)]
3.  Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47-53.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 1395]  [Cited by in RCA: 1756]  [Article Influence: 878.0]  [Reference Citation Analysis (10)]
4.  Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, Laversanne M, Ferlay J, Arnold M. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163:649-658.e2.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 968]  [Cited by in RCA: 925]  [Article Influence: 231.3]  [Reference Citation Analysis (16)]
5.  Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current Status and Future Prospects for Esophageal Cancer. Cancers (Basel). 2023;15:765.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 216]  [Cited by in RCA: 198]  [Article Influence: 66.0]  [Reference Citation Analysis (7)]
6.  Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:992-1004.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 567]  [Cited by in RCA: 552]  [Article Influence: 138.0]  [Reference Citation Analysis (6)]
7.  Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1674]  [Cited by in RCA: 1450]  [Article Influence: 42.6]  [Reference Citation Analysis (1)]
8.  Oshima K, Tsushima T, Ito Y, Kato K. Recent progress in chemoradiotherapy for oesophageal squamous cell carcinoma. Jpn J Clin Oncol. 2024;54:395-402.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 11]  [Cited by in RCA: 10]  [Article Influence: 5.0]  [Reference Citation Analysis (3)]
9.  Sasaki Y, Kato K. Chemoradiotherapy for esophageal squamous cell cancer. Jpn J Clin Oncol. 2016;46:805-810.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 24]  [Cited by in RCA: 39]  [Article Influence: 3.9]  [Reference Citation Analysis (1)]
10.  Zhang S, Shen Y, Zhu L, Lai Y, Zhu L, Xiao X, Li J, Tan W, Lin D, Wu C. Esophageal cancer: from pathogenesis to precision therapies. Signal Transduct Target Ther. 2026;11:134.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 3]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
11.  Hua Y, Liu Y, Liu Y, Tian X, Zhang X, You J, Yin F. Bibliometric analysis of immunotherapy for esophageal cancer: 2004-2024. Front Oncol. 2025;15:1565132.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 2]  [Reference Citation Analysis (3)]
12.  Makino T, Nakai S, Momose K, Yamashita K, Tanaka K, Miyata H, Yamamoto S, Motoori M, Kimura Y, Ushimaru Y, Hirao M, Matsuyama J, Akamaru Y, Kurokawa Y, Eguchi H, Doki Y. Efficacy and survival of nivolumab treatment for recurrent/unresectable esophageal squamous-cell carcinoma: real-world clinical data from a large multi-institutional cohort. Esophagus. 2024;21:319-327.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 9]  [Article Influence: 4.5]  [Reference Citation Analysis (0)]
13.  Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021;326:916-925.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 662]  [Cited by in RCA: 644]  [Article Influence: 128.8]  [Reference Citation Analysis (15)]
14.  Hsu CH, Lu Z, Gao S, Wang J, Sun JM, Liu T, Fan Q, Cai J, Ge F, Li S, Zhang L, Cha E, Allen S, Shen L. Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2026;27:103-115.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 11]  [Cited by in RCA: 14]  [Article Influence: 14.0]  [Reference Citation Analysis (4)]
15.  Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y, Liu M, Xi M. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023;24:371-382.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 91]  [Article Influence: 30.3]  [Reference Citation Analysis (3)]
16.  Chen B, Liu S, Zhu Y, Zhang J, Bao Y, Meng F, Zhang L, Cheng X, Xuzhang W, Chen B, Wang R, Li Z, Hu Y, Liu M, Lv Y, Li J, Dragomir MP, Chen M, Li Q, Yang H, Xi M. Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). J Clin Oncol. 2026;44:1508-1519.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2]  [Cited by in RCA: 4]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
17.  Sayer AA, Cooper R, Arai H, Cawthon PM, Ntsama Essomba MJ, Fielding RA, Grounds MD, Witham MD, Cruz-Jentoft AJ. Sarcopenia. Nat Rev Dis Primers. 2024;10:68.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 276]  [Cited by in RCA: 279]  [Article Influence: 139.5]  [Reference Citation Analysis (2)]
18.  Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol. 2016;26:1359-1367.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 140]  [Cited by in RCA: 179]  [Article Influence: 16.3]  [Reference Citation Analysis (0)]
19.  Nipp RD, Fuchs G, El-Jawahri A, Mario J, Troschel FM, Greer JA, Gallagher ER, Jackson VA, Kambadakone A, Hong TS, Temel JS, Fintelmann FJ. Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer. Oncologist. 2018;23:97-104.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 89]  [Cited by in RCA: 192]  [Article Influence: 21.3]  [Reference Citation Analysis (1)]
20.  Qu J, Liu Y, Yuan Y, Yu Z, Ding J, He Z, Wang G. Impacts of sarcopenia on adverse events and prognosis in Chinese patients with esophageal cancer undergoing chemoradiotherapy. Front Nutr. 2025;12:1523674.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 6]  [Reference Citation Analysis (1)]
21.  Xiao X, Fang PH, Zhou JF, Li XK, Shang QX, Yang YS, Luan SY, Chen LQ, Yuan Y. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation. Ann Surg Oncol. 2024;31:3819-3829.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 12]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
22.  Kosumi K, Baba Y, Hara Y, Wang H, Nomoto D, Toihata T, Ohuchi M, Harada K, Eto K, Ogawa K, Ishimoto T, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Baba H. Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors. Ann Surg Oncol. 2024;31:3839-3849.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 5]  [Reference Citation Analysis (1)]
23.  Watanabe A, Oshikiri T, Sawada R, Harada H, Urakawa N, Goto H, Hasegawa H, Kanaji S, Yamashita K, Matsuda T, Makiura D, Kakeji Y. Actual Sarcopenia Reflects Poor Prognosis in Patients with Esophageal Cancer. Ann Surg Oncol. 2022;29:3670-3681.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 1]  [Cited by in RCA: 12]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
24.  Fang P, Zhou J, Xiao X, Yang Y, Luan S, Liang Z, Li X, Zhang H, Shang Q, Zeng X, Yuan Y. The prognostic value of sarcopenia in oesophageal cancer: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2023;14:3-16.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 100]  [Cited by in RCA: 107]  [Article Influence: 35.7]  [Reference Citation Analysis (2)]
25.  Paschou SA, Andrikopoulou A, Mili N, Svarna A, Kaparelou M, Stefanaki K, Dedes N, Liatsou E, Thomakos N, Haidopoulos D, Psaltopoulou T, Kastritis E, Zagouri F, Dimopoulos MA, Liontos M. Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian Cancer. Nutrients. 2025;17:556.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 4]  [Reference Citation Analysis (0)]
26.  Li C, Zhong Y, Wang W, Jin X, Wang X. Short-term BMI trajectories as a prognostic predictor in patients with pancreatic cancer. Front Nutr. 2025;12:1680626.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (1)]
27.  Gu WS, Fang WZ, Liu CY, Pan KY, Ding R, Li XH, Duan CH. Prognostic significance of combined pretreatment body mass index (BMI) and BMI loss in patients with esophageal cancer. Cancer Manag Res. 2019;11:3029-3041.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 6]  [Cited by in RCA: 24]  [Article Influence: 3.4]  [Reference Citation Analysis (1)]
28.  Köylü B, Sulu C, Yumuk VD, Yumuk PF. The impact of sarcopenic obesity on cancer clinical outcomes. Semin Cancer Biol. 2025;114:203-214.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 4]  [Cited by in RCA: 6]  [Article Influence: 6.0]  [Reference Citation Analysis (0)]
29.  Zhao B, Bao L, Zhang T, Chen Y, Zhang S, Zhang C. Prevalence of sarcopenic obesity in patients with gastric cancer and effects on adverse outcomes: A meta-analysis and systematic review. Eur J Surg Oncol. 2024;50:108772.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 4]  [Cited by in RCA: 7]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
30.  Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629-635.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2721]  [Cited by in RCA: 2600]  [Article Influence: 144.4]  [Reference Citation Analysis (10)]
31.  Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539-1547.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 2294]  [Cited by in RCA: 2208]  [Article Influence: 169.8]  [Reference Citation Analysis (27)]
32.  Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21:300-307.e2.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 5704]  [Cited by in RCA: 5288]  [Article Influence: 881.3]  [Reference Citation Analysis (7)]
33.  Zhang FM, Zhang XZ, Shi HP, Zhang Z, Wang SL, Shen ZL, Chen XL, Shen X, Yu Z, Zhuang CL. Comparisons and Impacts of the Basic Components of Sarcopenia Definition and Their Pairwise Combinations in Gastric Cancer: A Large-Scale Study in a Chinese Population. Front Nutr. 2021;8:709211.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 8]  [Reference Citation Analysis (0)]
34.  Zhang S, Li W, Jia X, Zhang J, Jiang H, Wang L, Wang H, Zhang B, Wang Z, Ding G. Association of obesity profiles with type 2 diabetes in Chinese adults: Findings from the China health and nutrition survey. Front Nutr. 2022;9:922824.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 7]  [Reference Citation Analysis (0)]
35.  Xie HL, Ruan GT, Wei L, Zhang Q, Ge YZ, Song MM, Zhang X, Lin SQ, Liu XY, Zhang XW, Li XR, Zhang KP, Hu CL, Yang M, Tang M, Song CH, Cong MH, Weng M, Li ZN, Li W, Wang KH, Shi HP. The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia. J Cachexia Sarcopenia Muscle. 2023;14:879-890.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 21]  [Reference Citation Analysis (0)]
36.  Shah MA, Kennedy EB, Catenacci DV, Deighton DC, Goodman KA, Malhotra NK, Willett C, Stiles B, Sharma P, Tang L, Wijnhoven BPL, Hofstetter WL. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J Clin Oncol. 2020;38:2677-2694.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 273]  [Cited by in RCA: 245]  [Article Influence: 40.8]  [Reference Citation Analysis (2)]
37.  Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386:449-462.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 992]  [Cited by in RCA: 928]  [Article Influence: 232.0]  [Reference Citation Analysis (19)]
38.  Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in Crossref: 345]  [Cited by in RCA: 339]  [Article Influence: 84.8]  [Reference Citation Analysis (7)]
39.  Zeng Y, Chen J, Li L, Wang X, Ye Y, Xiong T, Ying W, Fu Z. Sarcopenia, myosteatosis and systemic immunoinflammatory index in the prediction of survival in patients undergoing immunotherapy for esophageal cancer. Sci Rep. 2026;16:4398.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Full Text (PDF)]  [Cited by in RCA: 1]  [Reference Citation Analysis (0)]
40.  Zhang H, Zhao J, Wang C, Zhang J, Zhu X, Li D, Han Z, Shang L, Shi Y. Association of past obesity and BMI trajectories with cancer mortality: a prospective cohort study. Arch Public Health. 2025;83:94.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in RCA: 3]  [Reference Citation Analysis (0)]
41.  Mintziras I, Miligkos M, Wächter S, Manoharan J, Maurer E, Bartsch DK. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis. Int J Surg. 2018;59:19-26.  [RCA]  [PubMed]  [DOI]  [Full Text]  [Cited by in Crossref: 179]  [Cited by in RCA: 168]  [Article Influence: 21.0]  [Reference Citation Analysis (5)]
Footnotes

Peer review: Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Oncology

Country of origin: China

Peer-review report’s classification

Scientific quality: Grade B, Grade B, Grade C

Novelty: Grade B, Grade B, Grade B

Creativity or innovation: Grade B, Grade B, Grade C

Scientific significance: Grade B, Grade B, Grade B

P-Reviewer: Chen H, MD, China; Srpcic M, Assistant Professor, Consultant, MD, PhD, Slovenia S-Editor: Bai Y L-Editor: A P-Editor: Yang YQ

Write to the Help Desk